|
|
|
|
|
by notlob
2904 days ago
|
|
One biotech person's perspective is that these are changes in the right direction. Things were certainly not perfect in the pre-AIA era, but post-AIA and recent court decisions have had many negative impacts on our industry, particularly diagnostics and particularly new ventures. The uncertainty associated with an “issued” patent has decimated their value, to the loss of innovation in our industry. |
|